Neptune Technologies & Bioresources Inc (NEPT) 2.41 $NEPT
Iroquois Capital Comments On Recent Schedule 13D Filing On Neptune Technologies & Bioresources Inc.
PR Newswire - Thu Apr 17, 7:39AM CDT
Iroquois Capital Management, LLC (together with its affiliates), a significant shareholder of Neptune Technologies & Bioressources Inc. "Neptune" (NASDAQ:NEPT), announced today that it had noted with interest and approval the Schedule 13D filing made recently by George W. Haywood and Messrs. Egan, O'Driscoll and Dobrich with respect to Neptune.
Neptune Announces Closing of CAD$2.5 Million Private Placement
GlobeNewswire - Fri Apr 04, 12:37PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today the closing of a private placement of CAD$2,503,320 of common shares of Neptune (the "Shares" at a price of CAD$2.76 per Share, resulting in a total of 907,000 Shares being issued today (the "Private Placement".
Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware.
Enzymotec Ltd. Provides Update on Patent Litigation With Neptune
GlobeNewswire - Tue Apr 01, 7:00AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company", a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that following a mediation process with Neptune Technologies & Bioressources, Inc. (Nasdaq:NEPT) ("Neptune", in conjunction with litigation in the U.S. International Trade Commission ("ITC", and based on latest developments regarding Neptune's patents in the U.S. Patent and Trademark Office ("USPTO", it has decided that it will not continue its efforts to negotiate a final settlement agreement with Neptune.
Why Neptune Technologies (NEPT) Is Up Today
at The Street - Thu Mar 27, 2:11PM CDT
Neptune Technologies (NEPT) rose on Thursday after the company announced the reconstruction of its Sherbrooke, Quebec, Canada facility would conclude on April 7. The life sciences company is in the process of conducting equipment and safety tests at...
Traders Get Bullish on Shares of Neptune Technologies & Bioressources-Ord, Shares Up 6.7% (NEPT)
Comtex SmarTrend(R) - Thu Mar 27, 11:41AM CDT
Neptune Technologies & Bioressources-Ord (AMEX:NEPT) is one of today's best performing low-priced stocks, up 6.7% to $2.39 on 1.1x average daily volume. Neptune Technologies & Bioressources-Ord has traded 690,000 shares thus far today, vs. average volume of 632,000 shares per day. The stock has outperformed the Dow (6.7% to the Dow's 0.0%) and outperformed the S&P 500 (6.7% to the S&P's -0.2%) during today's trading.
Neptune Provides Update on Sherbrooke Plant
GlobeNewswire - Thu Mar 27, 6:45AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB), announced today that reconstruction of its Sherbrooke, Quebec, Canada production facility will be completed April 7, 2014. Neptune is currently conducting equipment and safety related tests at the plant and employees are being trained. Preoperational testing will start early April 2014, with actual production commencing upon receipt of all outstanding permits.
NeuroBioPharm Extends Life of Warrants and Provides Other Corporate Updates
GlobeNewswire - Tue Mar 18, 1:14PM CDT
NeuroBioPharm Inc. ("NeuroBio" or the "Corporation", a Neptune Technologies & Bioressources Inc. subsidiary ("Neptune" (Nasdaq:NEPT) (TSX:NTB), announces that it has extended the life of its Series 2011-1 common share purchase warrants, initiated a royalty prepayment process with Neptune and appointed a new CFO.
Neptune Announces Closing of the Over-Allotment Option Associated with its Recently Completed Public Offering of Common Shares
PR Newswire - Thu Mar 06, 10:53AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (NASDAQ.NEPT - TSX.NTB), announced today that the syndicate of underwriters led by of Euro Pacific Canada Inc. and Roth Capital Partners, as Joint Book-Running Managers, and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD) as Lead Manager, have exercised in full the over-allotment option to purchase an additional 1,500,000 common shares of Neptune at a price of US$2.50 per common share in connection with Neptune's previously announced public offering, completed on March 5, 2014. As a result of the exercise of the over-allotment option, Neptune received additional gross proceeds of US$3.75 million for total gross proceeds of US$28.75 million.
Neptune Announces Closing of US$25.0 Million Underwritten Offering of Common Shares
CNW Group - Wed Mar 05, 8:11AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (NASDAQ.NEPT - TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today the closing of its previously announced public offering of 10,000,000 common shares at US$2.50 per common share for gross proceeds of US$25.0 million. Euro Pacific Canada Inc. and Roth Capital Partners, LLC acted as Joint Book-Running Managers for the offering and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD), acted as Lead Manager.
Neptune Announces Pricing of US$25 Million Offering of Common Shares
GlobeNewswire - Fri Feb 28, 7:34AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company" (Nasdaq:NEPT) (TSX:NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has priced an underwritten public offering of 10,000,000 newly issued common shares at a public offering price of US$2.50 per share.
Neptune Announces Proposed Offering of Common Shares
CNW Group - Thu Feb 27, 3:59PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company" (NASDAQ.NEPT) (TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has commenced an underwritten public offering of its common shares. The offering is being conducted in the United States pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission ("SEC" and in Canada pursuant to a final short form base shelf prospectus filed with the securities regulatory authorities in the Provinces of Québec, Ontario, Manitoba, Alberta and British Columbia. The number of common shares to be issued and the price of each common share will be determined at the time of pricing of the offering.
How Gunmen Killed 43 Students in Yobe
All Africa Global Media - Wed Feb 26, 1:32AM CST
Boko Haram cowards yesterday killed about 43 innocent students of the Federal Government College (FGC), Buni-Yadi in Gujba local government area of Yobe State.
Neptune Appoints John Moretz as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Tue Feb 18, 6:50AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (Nasdaq:NEPT) (TSX:NTB) announces the appointment of John Moretz as special advisor to its Board of Directors. Mr. Moretz has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholders approval.
Neptune and Acasti Provide Update on Patent Litigations With Enzymotec
GlobeNewswire - Fri Feb 14, 8:52AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
Acasti and Neptune Provide Update on Patent Litigations with Enzymotec
GlobeNewswire - Fri Feb 14, 8:40AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" (Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding.
AFET Ends Seed Banking Empowerment for Farmers
by Ebrima Bah - All Africa Global Media - Wed Jan 15, 8:02AM CST
The Association of Farmers, Educators and Traders (AFET) and Fandema has ended a twenty-day workshop on leadership and good governance for cooperative members and managers of certified seed growers in the provincial parts of The Gambia.
Iroquois Capital Comments On Recent Schedule 13D Filing On Neptune Technologies & Bioresources Inc.
PR Newswire - Thu Apr 17, 7:39AM CDT
Iroquois Capital Management, LLC (together with its affiliates), a significant shareholder of Neptune Technologies & Bioressources Inc. "Neptune" (NASDAQ:NEPT), announced today that it had noted with interest and approval the Schedule 13D filing made recently by George W. Haywood and Messrs. Egan, O'Driscoll and Dobrich with respect to Neptune.
Neptune Announces Closing of CAD$2.5 Million Private Placement
GlobeNewswire - Fri Apr 04, 12:37PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today the closing of a private placement of CAD$2,503,320 of common shares of Neptune (the "Shares" at a price of CAD$2.76 per Share, resulting in a total of 907,000 Shares being issued today (the "Private Placement". Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware. Enzymotec Ltd. Provides Update on Patent Litigation With Neptune
GlobeNewswire - Tue Apr 01, 7:00AM CDT
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"
, a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that following a mediation process with Neptune Technologies & Bioressources, Inc. (Nasdaq:NEPT) ("Neptune", in conjunction with litigation in the U.S. International Trade Commission ("ITC", and based on latest developments regarding Neptune's patents in the U.S. Patent and Trademark Office ("USPTO", it has decided that it will not continue its efforts to negotiate a final settlement agreement with Neptune. Why Neptune Technologies (NEPT) Is Up Today
at The Street - Thu Mar 27, 2:11PM CDT
Neptune Technologies (NEPT) rose on Thursday after the company announced the reconstruction of its Sherbrooke, Quebec, Canada facility would conclude on April 7. The life sciences company is in the process of conducting equipment and safety tests at...
Traders Get Bullish on Shares of Neptune Technologies & Bioressources-Ord, Shares Up 6.7% (NEPT)
Comtex SmarTrend(R) - Thu Mar 27, 11:41AM CDT
Neptune Technologies & Bioressources-Ord (AMEX:NEPT) is one of today's best performing low-priced stocks, up 6.7% to $2.39 on 1.1x average daily volume. Neptune Technologies & Bioressources-Ord has traded 690,000 shares thus far today, vs. average volume of 632,000 shares per day. The stock has outperformed the Dow (6.7% to the Dow's 0.0%) and outperformed the S&P 500 (6.7% to the S&P's -0.2%) during today's trading.
Neptune Provides Update on Sherbrooke Plant
GlobeNewswire - Thu Mar 27, 6:45AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB), announced today that reconstruction of its Sherbrooke, Quebec, Canada production facility will be completed April 7, 2014. Neptune is currently conducting equipment and safety related tests at the plant and employees are being trained. Preoperational testing will start early April 2014, with actual production commencing upon receipt of all outstanding permits. NeuroBioPharm Extends Life of Warrants and Provides Other Corporate Updates
GlobeNewswire - Tue Mar 18, 1:14PM CDT
NeuroBioPharm Inc. ("NeuroBio" or the "Corporation"
, a Neptune Technologies & Bioressources Inc. subsidiary ("Neptune" (Nasdaq:NEPT) (TSX:NTB), announces that it has extended the life of its Series 2011-1 common share purchase warrants, initiated a royalty prepayment process with Neptune and appointed a new CFO. Neptune Announces Closing of the Over-Allotment Option Associated with its Recently Completed Public Offering of Common Shares
PR Newswire - Thu Mar 06, 10:53AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(NASDAQ.NEPT - TSX.NTB), announced today that the syndicate of underwriters led by of Euro Pacific Canada Inc. and Roth Capital Partners, as Joint Book-Running Managers, and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD) as Lead Manager, have exercised in full the over-allotment option to purchase an additional 1,500,000 common shares of Neptune at a price of US$2.50 per common share in connection with Neptune's previously announced public offering, completed on March 5, 2014. As a result of the exercise of the over-allotment option, Neptune received additional gross proceeds of US$3.75 million for total gross proceeds of US$28.75 million. Neptune Announces Closing of US$25.0 Million Underwritten Offering of Common Shares
CNW Group - Wed Mar 05, 8:11AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(NASDAQ.NEPT - TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today the closing of its previously announced public offering of 10,000,000 common shares at US$2.50 per common share for gross proceeds of US$25.0 million. Euro Pacific Canada Inc. and Roth Capital Partners, LLC acted as Joint Book-Running Managers for the offering and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD), acted as Lead Manager. Neptune Announces Pricing of US$25 Million Offering of Common Shares
GlobeNewswire - Fri Feb 28, 7:34AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"
(Nasdaq:NEPT) (TSX:NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has priced an underwritten public offering of 10,000,000 newly issued common shares at a public offering price of US$2.50 per share. Neptune Announces Proposed Offering of Common Shares
CNW Group - Thu Feb 27, 3:59PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"
(NASDAQ.NEPT) (TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has commenced an underwritten public offering of its common shares. The offering is being conducted in the United States pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission ("SEC" and in Canada pursuant to a final short form base shelf prospectus filed with the securities regulatory authorities in the Provinces of Québec, Ontario, Manitoba, Alberta and British Columbia. The number of common shares to be issued and the price of each common share will be determined at the time of pricing of the offering. How Gunmen Killed 43 Students in Yobe
All Africa Global Media - Wed Feb 26, 1:32AM CST
Boko Haram cowards yesterday killed about 43 innocent students of the Federal Government College (FGC), Buni-Yadi in Gujba local government area of Yobe State.
Neptune Appoints John Moretz as Special Advisor and Nominee to Its Board of Directors
GlobeNewswire - Tue Feb 18, 6:50AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(Nasdaq:NEPT) (TSX:NTB) announces the appointment of John Moretz as special advisor to its Board of Directors. Mr. Moretz has also accepted the nomination for election to serve on the Corporation's Board of Directors at the next Annual Meeting to be held in 2014, subject to shareholders approval. Neptune and Acasti Provide Update on Patent Litigations With Enzymotec
GlobeNewswire - Fri Feb 14, 8:52AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding. Acasti and Neptune Provide Update on Patent Litigations with Enzymotec
GlobeNewswire - Fri Feb 14, 8:40AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"
(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti" (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that a settlement agreement has not been finalized with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec" that would resolve the International Trade Commission ("ITC" investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. The ITC investigation was instituted in early 2013 after Neptune and Acasti's filing of a complaint alleging infringement of Neptune's krill extract composition patents by Enzymotec and other industry players, including Aker BioMarine and Rimfrost USA, LLC. As previously announced, Neptune and Acasti have concluded settlement agreements with all other Respondents named in the ITC investigation, and motions to terminate the ITC investigation as to these companies have been granted. Only Enzymotec remains outstanding. AFET Ends Seed Banking Empowerment for Farmers
by Ebrima Bah - All Africa Global Media - Wed Jan 15, 8:02AM CST
The Association of Farmers, Educators and Traders (AFET) and Fandema has ended a twenty-day workshop on leadership and good governance for cooperative members and managers of certified seed growers in the provincial parts of The Gambia.
